Santen Pharmaceutical has been granted a patent for an implantable device designed to treat glaucoma. The device includes a flexible tube with a structure extending radially outward in multiple directions, allowing it to divert aqueous humor from the eye’s anterior chamber. The structure is designed to seal to surrounding ocular tissue, preventing leakage of aqueous humor. The device also features a tapered profile to facilitate insertion into the tissue passage. GlobalData’s report on Santen Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Santen Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Santen Pharmaceutical's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Implantable device for glaucoma treatment with aqueous humor drainage
A recently granted patent (Publication Number: US11717441B2) describes an aqueous humor drainage device for implantation into the anterior chamber of the eye. The device consists of a flexible tube and a structure that extends radially outward from the tube in at least two different directions. The tube has a central axis and a proximal portion and a distal portion, both with cylindrical outer surfaces. The structure is spaced apart from the cylindrical outer surfaces of the tube and has a larger cross-sectional dimension than the tube. The structure has a blunt outer surface with rounded features to avoid sharp corners and edges, allowing it to seal to surrounding ocular tissue and prevent leakage of aqueous humor. The device also has a tapered profile at the distal end of the tube to facilitate insertion into the tissue passage.
The patent claims also describe variations of the device, including different cross-sectional shapes for the structure, such as circular, rhomboid, oblong, semi-elliptical, and ovoid. The structure can have a third maximal cross-sectional dimension that is smaller than the second maximal cross-sectional dimension. The first maximal cross-sectional dimension of the tube is no more than 0.4 mm, while the second maximal cross-sectional dimension of the structure is at least 0.9 mm. The tube can be made from various polymeric materials, including SIBS material, silicone rubber, polyolefin, polyurethane, acrylic, fluoropolymer, polyamide, hydrogel, biological-based structures, soft polymer foam, porous polymer, or combinations thereof.
Another embodiment of the device includes a flexible tube and first and second tabs. The tabs are spaced apart from the cylindrical outer surfaces of the tube and extend radially outward beyond them. The tabs have a larger cross-sectional dimension than the tube and have blunt outer surfaces with rounded features. They are designed to seal to surrounding ocular tissue and prevent leakage of aqueous humor. The tabs are generally planar and extend transverse to the central axis of the tube. They can fit entirely within the tissue passage and have a maximal thickness no more than the first maximal cross-sectional diameter of the tube. The distal surfaces of the tabs have a tapered profile that extends away from the distal portion of the tube toward the proximal portion.
Overall, this patent describes an aqueous humor drainage device with a flexible tube and a structure or tabs that seal to surrounding ocular tissue to prevent leakage of aqueous humor. The device has various configurations and cross-sectional shapes, allowing for customization based on individual patient needs.
To know more about GlobalData’s detailed insights on Santen Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
